Fig. 2: CFI-400945 treatment triggers mitotic defects. | Cell Death & Disease

Fig. 2: CFI-400945 treatment triggers mitotic defects.

From: Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

Fig. 2

a Cell cycle profiles of DLBCL cell lines after treatment with 0, 10, 20, and 50 nM CFI-400945 for 48 h. b Flow cytometer analysis of DNA content of LY8 and LY3 after treatment with CFI-400945 for 48 h. The proportions of cells in each cell cycle fraction were analyzed. c Immunofluorescence staining of Phalloidin and DAPI demonstrated binucleated cells in CFI-400945-treated LY8 cells. Statistics of bi- and multi-nucleated cells were shown on the right. Scale bar: 5 μm. d Western blot showed an increase in Serine 15 phosphorylation of p53, accompanied by upregulated expression levels of p53 and p21 upon CFI-400945 treatment. e Western blot showed the levels of phospho-LATS1, phospho-YAP, and total-LATS1, total-YAP in CFI-400945-treated LY8 cells. f Confocal microscopy showed translocation of YAP from nucleus to cytosol in LY8 cells upon CFI-400945 treatment, with analysis of the percentage of cells with predominantly nuclear YAP shown in the right panel. Scale bar: 5 μm. g Nuclear/cytosol fractionation detected by western blot confirmed translocation of YAP upon CFI-400945 treatment. Data are shown as the mean ± SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page